Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[30/10/2018]

UCB : UCB Media Room: Q3 Results

UCB First Nine Months Interim Report 2018:UCB tracking well towards full year financial outlookBrussels Belgium, 30 October 2018 – 7:00 am CET – regulated information –Revenue reached € 3.4 billion 3%; 6% CERStrong growth of UCB’s five main products reached € 2.8 billion 6%; 12% CERR&D update: Cimzia® filed for nonradiographic axial spondyloarthritis nraxSpA in the U.S.; Keppra®... See more
 
UCB [BE0003739530/UCB]   
[24/10/2018]

UCB : UCB Media Room: ACR bimekizumab

Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis PatientsIn the first presentation of longterm data for UCB’s investigational molecule bimekizumab, latebreaking results from the Phase 2b BE ACTIVE study showed promising response rates that increased up to Week 24 and were maintained to Week 48 across disease manifestations in psoriatic... See more
 
UCB [BE0003739530/UCB]   
[23/10/2018]

UCB : UCB Media Room: Topline Results from a Phase 2b Study of Dapirolizumab Pegol in SLE

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus ErythematosusBrussels, Belgium and Cambridge, MA – 23 October 2018, 7:00 AM CEST – Today UCB Euronext Brussels: UCB and Biogen Inc. Nasdaq: BIIB announced topline results from a Phase 2b study evaluating the safety and efficacy of dapirolizumab pegol DZP, an antiCD40L pegylated Fab, in... See more
 
UCB [BE0003739530/UCB]   
[19/10/2018]

UCB : UCB Media Room: ACR Data Highlights

UCB Presents New LongTerm Data Showing Substantial Impact for CIMZIA® Certolizumab Pegol in Axial Spondyloarthritis and Rheumatoid Arthritis and LateBreaking Bimekizumab Data in Psoriatic ArthritisOral presentation of results from CAXSPAND, the first Phase 3 study to follow nonradiographic axial spondyloarthritis nraxSpA patients for 52 weeks, demonstrated positive results for CIMZIA®... See more
 
UCB [BE0003739530/UCB]   
[18/10/2018]

UCB : UCB Media Room: World Osteoporosis Day

The impact of fragility fractures due to osteoporosis is being ignoredNew survey reveals that 61 per cent of women over 60 have little or no knowledge of osteoporosis, despite the fact that one in three is likely to develop a fragility fracture due to the conditionOver half 55 per cent of respondents believe that fragility fractures in older age are a result of an unlucky fall or accident, rather... See more